ATP2A2

Across TCGA pan-cancer cohorts, ATP2A2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP2A2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ATP2A2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ATP2A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

UCEC, COAD, and ESCA are the cancer types where ATP2A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.823	.001	32	view →
COAD	OS	Median	All	0.054	0.871	<.001	25	view →
ESCA	OS	Median	II,III,IV	0.206	0.686	.004	12	view →
LIHC	OS	Median	All	0.255	0.773	.012	6	view →
LUSC	OS	Median	All	1.000	0.769	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP2A2–UCEC (DFS)

Open the UCEC breakdown →